Effects of RAS and SGLT2 inhibitors alone or in combination on end-stage kidney disease and/or all-cause death in patients with both diabetes and hypertension: a nationwide cohort study
- Cardiovasc. Diabetol., 14 July 2025 | https://doi.org/10.1186/s12933-025-02846-x